Original Publication Date: 1 August, 2014
Publication / Source: Lung Cancer Management
Authors: Weiqiang Zhao, Senthilkumar Damodaran, Miguel A Villalona-Calero
Molecular selection has led to the successful use of novel tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancers (NSCLCs). For instance, mutations in EGFR and translocations and fusions in ALK render tumor cells sensitive to some TKIs, leading to substantial clinical benefits. Molecular testing such as DNA sequencing or fragment analysis following PCR, and evaluation of copy number and gene positioning by FISH, have been developed and used clinically to identify mutations/fusions.